Generic medication for crestor
Pro Research Analysisby 
Searched over 200M research papers
Consensus Meter
Generic Medication for Crestor: An Overview
Introduction to Crestor and Its Patent Challenges
Crestor, known generically as rosuvastatin, is a widely used cholesterol-lowering medication. AstraZeneca, the manufacturer of Crestor, has faced legal challenges from several generic drug manufacturers, including Aurobindo, Apotex, Cobalt, Par, Sandoz, Mylan, and Sun. These companies have sought approval from the US FDA to market generic versions of Crestor, arguing that the patent held by AstraZeneca is either invalid, unenforceable, or not infringed. Despite these challenges, the patent for Crestor was not set to expire until 2016, allowing AstraZeneca to maintain its market position for a significant period.
Comparative Efficacy and Safety of Generic Rosuvastatin
A study conducted by the Russian Scientific Medical Society of Internal Medicine compared the efficacy and safety of the generic rosuvastatin compound Akorta with the original Crestor. The study included 60 patients with dyslipidemia and utilized a randomized crossover design over 14 weeks. The results demonstrated that both Akorta and Crestor were equally effective in reducing low-density lipoprotein cholesterol (LDL-C) levels. Specifically, the LDL-C reduction rates were 49.0% for Akorta and 52.6% for Crestor after the first treatment period, and 47.2% for Akorta and 43.4% for Crestor after the second period. Additionally, the safety profiles of both medications were comparable, indicating that the generic version is a viable alternative to the original.
Impact of Lipitor’s Patent Expiration on Crestor Demand
The expiration of Lipitor’s patent, another statin medication, raised questions about its impact on the demand for Crestor. Research using data from the Medical Expenditure Panel Survey found that the overall market for Crestor was not significantly affected by Lipitor’s patent expiration. However, there was a notable reduction in Crestor usage among patients with private insurance (approximately 13%) and Medicaid patients. Interestingly, the strength of a typical Crestor pill increased by 18%, which could be seen as a de facto price decrease, making Crestor more competitive against generic alternatives.
Conclusion
The introduction of generic versions of Crestor, such as Akorta, has shown to be effective and safe, providing a cost-effective alternative for patients needing cholesterol-lowering treatment. Despite legal challenges and market shifts due to the expiration of patents for other statins like Lipitor, Crestor has maintained its presence in the market. The availability of generics is likely to continue influencing the dynamics of cholesterol-lowering medications, offering more options for patients and potentially reducing overall drug spending.
Sources and full results
Most relevant research papers on this topic